The emerging role of HLA-C in HIV-1 infection

Immunology

Volumn 134, Issue 2, 2011, Pages 116-122

  Kulpa, Deanna A ^a   Collins, Kathleen L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

35SNP; HIV; HLA C; KIR; MHC I

Indexed keywords

HLA C ANTIGEN; MICRORNA;

ALLELE; ANTIGEN EXPRESSION; BINDING SITE; DISEASE COURSE; GENE; GENE LOCUS; HLA C GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

AMINO ACID SEQUENCE; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MICRORNAS; MOLECULAR SEQUENCE DATA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80052465652     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03474.x     Document Type: Review

References (66)

1. The International HIVCS. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-7.
2. Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-7.
3. Fellay J, Ge D, Shianna KV et al. Common genetic variation and the Control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
4. Adams EJ, Parham P. Species-specific evolution of MHC class I genes in the higher primates. Immunol Rev 2001; 183:41-64.
5. Hughes AL, Nei M. Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. Nature 1988; 335:167-70.
6. Older Aguilar AM, Guethlein LA, Adams EJ, Abi-Rached L, Moesta AK, Parham P. Coevolution of killer cell Ig-like receptors with HLA-C to become the major variable regulators of human NK cells. J Immunol 2010; 185:4238-51.
7. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14:619-48.
8. Blais M-E, Dong T, Rowland-Jones SL. HLA-C as a mediator of natural killer and T-cell activation: spectator or key player? Immunology 2011; 133:1-7.
9. Snary D, Barnstable CJ, Bodmer WF, Crumpton MJ. Molecular structure of human histocompatibility antigens: the HLA-C series. Eur J Immunol 1977; 7:580-5.
10. McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med 1995; 181:2085-95.
11. Neisig A, Melief CJM, Neefjes J. Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J Immunol 1998; 160:171-9.
12. Kulkarni S, Savan R, Qi Y et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011; 472:495-8.
13. Neefjes JJ, Ploegh HL. Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with β2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association. Eur J Immunol 1988; 18:801-10.
14. Setini A, Beretta A, De Santis C et al. Distinctive features of the α1-domain a helix of HLA-C heavy chains free of β2-microglobulin. Hum Immunol 1996; 46:69-81.
15. Shimizu Y, DeMars R. Production of human cells expressing individual transferred HLA-A, -B, -C genes using an HLA-A, -B, -C null human cell line. J Immunol 1989; 142:3320-8.
16. Schaefer MR, Williams M, Kulpa DA, Blakely PK, Yaffee AQ, Collins KL. A novel trafficking signal within the HLA-C cytoplasmic tail allows regulated expression upon differentiation of macrophages. J Immunol 2008; 180:7804-17.
17. + T cells. J Immunol 2004; 173:7223-9.
18. Alter G, Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med 2009; 265:29-42.
19. Carrington M, Martin MP, van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol 2008; 16:620-7.
20. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872-4.
21. Lopez-Vazquez A, Rodrigo L, Martinez-Borra J et al. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 2005; 192:162-5.
22. Martin AM, Freitas EM, Witt CS, Christiansen FT. The genomic organization and evolution of the natural killer immunoglobulin-like receptor (KIR) gene cluster. Immunogenetics 2000; 51:268-80.
23. Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 2002; 190:40-52.
24. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 1998; 161:571-7.
25. Andersson S, Fauriat JA, Malmberg HG, Ljunggren HG, Malmberg KJ. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 2009; 114:95-104.
26. Anfossi N, André P, Guia S et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-42.
27. Yawata M, Yawata N, Draghi M, Little A-M, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203:633-45.
28. Carneiro VL, Lemaire DC, Bendicho MT et al. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver Int 2010; 30:567-73.
29. Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors. Transpl Immunol 2002; 10:147-64.
30. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998; 391:397-401.
31. Herschhorn A, Marasco WA, Hizi A. Antibodies and lentiviruses that specifically recognize a T cell epitope derived from HIV-1 Nef protein and presented by HLA-C. J Immunol 2010; 185:7623-32.
32. Roeth JF, Williams M, Kasper MR, Filzen TM, Collins KL. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J Cell Biol 2004; 167:903-13.
33. Wonderlich ER, Williams M, Collins KL. The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu1 subunit is necessary for Nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail. J Biol Chem 2008; 283:3011-22.
34. Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard J-M, Schwartz O. Nef interacts with the μ subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998; 8:483-95.
35. Lifson JD, Nowak MA, Goldstein S et al. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 1997; 71:9508-14.
36. + T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11:1799-806.
37. van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MAM, van't Wout A, Schuitemaker H. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009; 23:19-28.
38. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
39. Klein MR, Miedema F. Long-term survivors of HIV-1 infection. Trends Microbiol 1995; 3:386-91.
40. Munoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997; 11(Suppl. A):S69-76.
41. Concerted AoStAaDiE. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355:1131-7.
42. Veugelers PJ, Page KA, Tindall B et al. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol 1994; 140:747-58.
43. Han Y, Lai J, Barditch-Crovo P, Gallant JE, Williams TM, Siliciano RF, Blankson JN. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS 2008; 22:541-4.
44. Corrah TW, Goonetilleke N, Kopycinski J, Deeks SG, Cohen MS, Borrow P, McMichael A, Brackenridge S. A reappraisal of the relationship between the HIV-1-protective single nucleotide polymorphism 35kb upstream of the HLA-C gene and surface HLA-C expression. J Virol 2011; 85:3367-74.
45. Stranger BE, Forrest MS, Clark AG et al. Genome-wide associations of gene expression variation in humans. PLoS Genet 2005; 1:e78.
46. Thomas R, Apps R, Qi Y et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009; 41:1290-4.
47. Specht A, Telenti A, Martinez R et al. Counteraction of HLA-C-mediated immune control of HIV-1 by Nef. J Virol 2010; 84:7300-11.
48. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
49. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005; 79:13239-49.
50. Bansal A, Yue L, Conway J et al. Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents. AIDS 2007; 21:2387-97.
51. Moore CB, Johh M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296:1439-43.
52. Bhattacharya T, Daniels M, Heckerman D et al. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007; 315:1583-6.
53. Leslie AJ, Pfafferott KJ, Chetty P et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:282-9.
54. Brumme ZL, Brumme CJ, Heckerman D et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007; 3:e94.
55. Novitsky V, Wang R, Margolin L et al. Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection. PLoS ONE 2009; 4:e7727.
56. Treurnicht FK, Seoighe C, Martin DP et al. Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure. Virology 2010; 396:213-25.
57. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53.
58. + T-cell epitopes. J Virol 2007; 81:3667-72.
59. Adnan S, Balamurugan A, Trocha A, Bennett MS, Ng HL, Brander C, Yang OO. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood 2006; 108:3414-19.
60. Rousseau CM, Daniels MG, Carlson JM et al. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype C proteome: immune escape and viral load. J Virol 2008; 82:6434-46.
61. Makadzange AT, Gillespie G, Dong T et al. Characterization of an HLA-C-restricted CTL response in chronic HIV infection. Eur J Immunol 2010; 40:1036-41.
62. Kelleher AD, Long C, Holmes EC et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193:375-86.
63. Martinez-Picado J, Prado JG, Fry EE et al. Fitness cost of escape mutations in p24 gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617-23.
64. + T-cell responses targeting the HIV-1 gag major homology region drive virus immune escape and fitness constraints compensated for by intracodon variation. J Virol 2010; 84:11279-88.
65. Honda K, Zheng N, Murakoshi H et al. Selection of escape mutant by HLC-C-restricted HIV-1 Pol-specific cytotoxic T lymphocytes carrying strong ability to suppress HIV-1 replication. Eur J Immunol 2011; 41:97-106.
66. Martin M, Borecki I, Zhang Z et al. HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. Immunogenetics 2010; 62:761-5.